Skip to main content
OpenTrials
Completed

NCT Number: NCT07071701

A Clinical Trial to Observe the Safety of 23-Valent Pneumococcal Polysaccharide Vaccine in Target Population

An open clinical trial of a 23-valent pneumococcal polysaccharide vaccine (PPV23) developed by Sinovac Life Science Co., Ltd was conducted to evaluate the safety of Sinovac PPV23 in target population of individuals aged 2 years and above. All participants received 1 dose of PPV23 and self-selected whether to receive 1 dose of influenza vaccine at the same time.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pneumococcal Infectious Disease Bacterial Infections Bacterial Infections and Mycoses Gram-Positive Bacterial Infections Infections Pneumococcal Infections Streptococcal Infections

Age range

2 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Jiangsu Provincial Center for Disease Prevention and Control

Nanjing, Jiangsu, China

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Have voluntarily and at their own expense received the 23-valent pneumococcal polysaccharide vaccine;
  • Participants and/or their guardians are able to understand and voluntarily participate in this study and sign an informed consent form;
  • Provide valid legal identification.

Treatment and study plan

23-valent pneumococcal polysaccharide vaccine

Biological

23-valent pneumococcal polysaccharide vaccine

influenza vaccine

Biological

Influenza vaccine

Primary outcomes

  1. Incidence of adverse reactions to 23-valent pneumonia vaccine within 0-28 days after single and combined vaccination.

    Time frame: 28 days after the vaccination

Secondary outcomes

  1. Incidence of adverse events to 23-valent pneumonia vaccine within 0-28 days after single and combined vaccination.

    Time frame: 28 days after the vaccination

  2. Incidence of adverse events to 23-valent pneumonia vaccine within 0-7 days after single and combined vaccination.

    Time frame: 7 days after the vaccination

Sponsors and collaborators

Lead sponsor

Sinovac Biotech Co., Ltd

Industry

Registry information

Official study title

A Clinical Trial to Observe the Safety of 23-Valent Pneumococcal Polysaccharide Vaccine in Target Population Aged 2 Years and Above

Important dates

Study start
2022
Primary completion
2024
Study completion
2024
First posted
Jul 17, 2025
Registry last updated
Jul 17, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.